Chonluten

Glu-Asp-Gly, EDG, "bronchial/lung tripeptide", T-34 (older code in some Russian sources) †

Immune & bioregulators

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Summary

Class: Synthetic tripeptide (3 amino acids: glutamate-aspartate-glycine) from the Khavinson "cytogen" family
Mechanism: Proposed to regulate gene expression in bronchial and gastric epithelium — including antioxidant and anti-inflammatory genes — via DNA binding; cell and rodent data from one group
Routes studied: Injection (rodents); oral capsules (marketed form in Russia); inhaled/intranasal proposed in the group's 2020 COVID-19 review, not tested
Dose range reported: Rodent and cell studies: nanogram-to-microgram range. Community-reported: 1–2 capsules/day for 10–30 days. No validated human dose
Half-life: Not characterised; tripeptides are expected to be degraded in plasma within minutes
Storage: Lyophilised: refrigerate, protect from light. Capsules: room temperature, dry
Regulatory status: Not approved as a medicine anywhere. Sold in Russia as a food supplement †. See region table

Doses are as reported in studies or by the community — never recommendations.

1What it is

Chonluten is a three-amino-acid synthetic peptide designed by the Khavinson group in St Petersburg as a "bioregulator" for the respiratory system, with a secondary claim for the stomach and gut lining. The name has no chemical meaning; it is a product name. The sequence Glu-Asp-Gly is close to that of several other Khavinson peptides (Epitalon is Ala-Glu-Asp-Gly; Bronchogen is Ala-Glu-Asp-Leu), which is why the group's work on one often cites the others.

As with all compounds in this family, almost every publication is from the originating group or its collaborators, much of it in Russian. There is no independent replication that we are aware of, and no human trial.

2How it's thought to work

The group proposes that the peptide crosses cell and nuclear membranes and binds specific DNA sequences, changing transcription (see Cardiogen for the general model).

For Chonluten the reported targets are genes involved in antioxidant defence, cell proliferation and inflammation in bronchial epithelium — the group describes changes in expression of markers such as Ki-67 (proliferation) and antioxidant enzymes in culture (Khavinson 2012; Khavinson 2020).

The gut claim rests on rodent gastric-mucosa models in older Russian-language work and on the idea that the peptide protects epithelial cells against oxidative stress generally.

In its 2020 review on peptides for COVID-19 the group grouped Chonluten with Bronchogen and Thymalin as candidates for lung protection; this was a proposal, not a result (Khavinson 2020, Molecules).

Proposed: a tripeptide directed at the lung lining, reported in Russian work to normalise gene expression in bronchial cells. Not independently confirmed.Schematic — not to scale

3What the research shows

Bronchial epithelial cell biology

Cell-culture studies from the originating group report that Chonluten and related peptides alter proliferation and differentiation markers in bronchial epithelial cells, in an age-dependent manner (Khavinson 2012, Bull Exp Biol Med; Khavinson 2020, Stem Cell Rev Rep). only. [3][4][5]

Lung tissue in rodents

Rodent work summarised in the group's reviews reports improved epithelial structure and antioxidant indices in ageing or injured lung. Primary data are largely in Russian and difficult to appraise (Khavinson & Malinin 2005; Anisimov & Khavinson 2010). [1][2]

Gastric mucosa protection

Older rodent data from the group report reduced ulceration and improved mucosal repair. This is the basis of the "gut" label. Single group; no independent replication; no human data.

Respiratory infection, COPD, asthma in humans

No controlled human trials. Russian-language clinical observations of the extract-based predecessors exist but are uncontrolled. Community reports mention easier breathing or fewer winter infections; anecdotal. The literature is thin; we have not padded it.

4Reported side effects and interactions

Literature-reported

No adverse effects reported in the group's animal or cell studies. No peer-reviewed human safety data.

Community-reported

Almost none; the few reports describe no noticeable effects, positive or negative.

Theoretical. A compound said to increase epithelial proliferation would, in principle, deserve caution in people with a history of lung or gastric malignancy; nothing has been measured.

Interactions. None established.

Markers researchers commonly monitor

No compound-specific markers are established. Commonly discussed:

Marker	Why it's watched
Spirometry (FEV1/FVC) or a home peak-flow meter	the claimed organ is the lung; peak flow is a cheap, repeatable objective measure.
Resting oxygen saturation (pulse oximeter)	easy daily baseline for anyone using it for respiratory reasons.
hs-CRP	general inflammation marker; the group's rationale is anti-inflammatory.
CBC and CMP	general baseline for any compound with no human safety data.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

The marketed form in Russia is an oral capsule; injectable vials (typically 10–20 mg) also circulate. For vials, with , swirl gently, refrigerate and protect from light. Capsules need no preparation.

Open in calculator, pre-loaded →

6Commonly studied alongside

Bronchogen (#83) — the group often pairs the two for the respiratory system; Thymalin or Thymogen for immune support in the group's protocols; Epitalon (#13). No combination has been studied in humans.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Not FDA-approved; not a permitted dietary supplement ingredient. Not on the FDA 2023 Category 2 compounding list to our knowledge †
European Union	Not authorised; not a permitted food/supplement ingredient
United Kingdom	Not licensed
Australia	Not approved †
South Africa	Not registered with SAHPRA
Sport (WADA)	Not specifically named; S0 as a non-approved substance †

8Open questions

Does oral Chonluten survive digestion and reach lung or gut epithelium intact? No pharmacokinetic study exists.
Can the gene-expression effects be replicated independently?
Any human respiratory or gastric outcome at all — none has been measured in a controlled design.

9References

1Khavinson VKh, Malinin VV (2005). Gerontological Aspects of Genome Peptide Regulation. Karger, Basel. DOI
2Anisimov VN, Khavinson VKh (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. PubMed · DOI
3Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. PubMed · DOI
4Khavinson V, Linkova N, Diatlova A, Trofimova S (2020). Peptide regulation of cell differentiation. Stem Cell Rev Rep. PubMed · DOI
5Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. PubMed · DOI
6Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Peptide regulation of gene expression: a systematic review. Molecules. PubMed · DOI

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

26 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.